In the near future increasing number of elderly patients with haematological malignancies will require chemotherapy and/or radiotherapy. The high dose or even standard chemotherapy usually results in higher, than in younger patients, percentage of life-threatening myelosupression and deaths. This phenomenon in elderly patients is not clear. There are reports suggesting that in elderly patients age-related changes are not so different comparing to younger subjects. In elderly patients anti-tumour response is reduced but function of dendritic cells in these patients is preserved. It seems that cell- based immunotherapy might be a promising therapeutic option for age-advanced cancer patients. In this paper we shortly reviewed some age-specific haematological malignancies.